Pilot randomized controlled trial of the prevention of early respiratory tract infections in intubated patients. Comparison of the safety and efficacy of a short course of systemic antibiotic, a cough simulator and aspiration of subglottic secretions
This important study is investigating new ways to protect very unwell patients in intensive care who are on breathing machines (intubated). These patients often have serious conditions like severe injuries, strokes, or cardiac arrest, which can make them more vulnerable to lung infections. The research team is comparing a short course of a specific antibiotic with special techniques like a 'cough simulator' and removing fluid from airways. The main goal is to find out if these methods are safe and effective at preventing lung infections like pneumonia and tracheobronchitis within the first two weeks. They will also look at how long patients need breathing support and their overall recovery.
At a glance
What is this study about?
When someone is very poorly, perhaps after a serious accident, a stroke, or a heart attack, they might need help breathing. This often means inserting a tube into their windpipe and connecting them to a breathing machine, a process called intubation. While lifesavers, breathing machines can sometimes unfortunately increase the risk of developing lung infections like pneumonia or an infection of the windpipe (tracheobronchitis). These infections can make recovery even harder.
This study aims to discover the best ways to prevent these infections from happening in the first place. Researchers are testing a few different approaches. One group of patients might receive a short course of an antibiotic (a medicine to fight bacteria), while another group might receive treatments that help clear their airways, like a special 'cough simulator' or a gentle suctioning procedure to remove fluid. The main thing the researchers want to understand is which of these methods is safest and most effective in reducing the number of these infections within the first couple of weeks after a patient is intubated.
This is a 'Phase IV' study, which means the treatments being tested are already known and used in medicine. The study is focused on how well they work and their safety in this specific group of very sick patients. Ultimately, the hope is to find better ways to protect vulnerable patients and help them recover more smoothly.
Key takeaways
- Study aims to prevent lung infections in very sick patients on breathing machines.
- It compares an antibiotic with airway-clearing treatments.
- Focuses on patient safety and reducing infections like pneumonia.
- Patients are followed for up to 90 days to check recovery.
- The treatments being studied are already established medications/procedures.
Who may be eligible?
This study is for adults aged 18 and over, both men and women, who are currently in intensive care. To be considered for this study, patients must have a reduced level of consciousness, meaning they are not fully awake or alert due to a serious medical event.
This serious event could be something like a severe injury, a traumatic brain injury, a stroke, or a cardiac arrest (when the heart stops beating). Patients must also be intubated, meaning they have a breathing tube in place to help them breathe.
There might be other specific health conditions that would mean a patient couldn't join the study, but the healthcare team would go through all these details carefully with the patient's family or legal representative.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Is the patient 18 years old or older?
- Is the patient currently in intensive care?
- Does the patient have a reduced level of consciousness (e.g., from severe injury, stroke, or cardiac arrest)?
- Is the patient currently on a breathing machine (intubated)?
What does participation involve?
If a patient is eligible for this study, their family or legal representative would be asked for permission. If they agree, the patient would then be randomly assigned to one of the study groups. This means they would either receive a short course of the antibiotic, or they would receive one of the airway-clearing treatments (cough simulator or subglottic aspiration). These treatments would already be part of their ongoing care.
The research team will closely monitor the patient's health, particularly looking for any signs of lung infection or any reactions to the treatment, for 14 days after joining the study. They will also track how long the patient needs breathing support, their time in intensive care, and their recovery journey up to 90 days. This involves collecting routine information from their medical records. There will be no extra hospital visits beyond what is already planned for their care.
Potential risks and benefits
Locations (1)
- —UnverifiedSpain
Common questions
What is 'intubation'?
Intubation means a tube is placed into a patient's windpipe to help them breathe, usually connected to a breathing machine.
What is 'pneumonia'?
Pneumonia is a serious lung infection that can make it hard to breathe.
What does a 'cough simulator' do?
A cough simulator is a device that helps patients clear their airways by gently mimicking a natural cough.
Is the antibiotic used in this study new?
No, the antibiotic (ceftriaxone) is already a commonly used medicine, but its use in this specific way is being studied.
How long will the study follow patients?
Patients' health and recovery will be monitored for up to 90 days after joining the study.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.